Skip to content
Back to News Hub
Biotechnology

Corporate Presentation June 2025

CLEO DIAGNOSTICS LTD < 1 mins read
 
Cleo Diagnostics shares its updated June 2025 corporate presentation outlining the Company's strategy and progress on "Pioneering the Transformation of Ovarian Cancer Detection." 
 
The clinical unmet need for a screening solution for Ovarian Cancer is urgent.
 
Critically, no effective screening test currently exists, with the only way to definitively diagnose Ovarian Cancer being after surgery.
 
51% of women continue to die within 5 years of an Ovarian Cancer diagnosis. That’s 6 times higher than for Breast Cancer which has a mortality rate of only 8%. 
 
CLEO’s disruptive patented technology offers superior performance to current clinical tests with the Company advancing its plans to address a critical unmet need on a global scale.
 
Link to presentation: bit.ly/43Gikp9
 
 
Media and Investors contact:

Dayna Louca
Head of Corporate Development
Cleo Diagnostics Limited
[email protected]

Media

More from this category

  • Biotechnology, Business Company News
  • 08/07/2025
  • 10:02
Jane Morgan Management

BlinkLab Expands U.S. Clinical Trial Network – University of Nebraska Medical Center Engaged as Second Site in Main Phase of FDA 510(k) Study

BlinkLab Limited (ASX:BB1) (“BlinkLab” or “the Company”) is pleased to announce the expansion of its U.S. clinical trial network with the University of Nebraska Medical Center (UNMC) engaged as the second site in the main phase of its FDA 510(k) study for BlinkLab Dx 1 – its smartphone-based diagnostic tool for early autism detection. Highlights Second U.S. Site: University of Nebraska Medical Center (UNMC) selected as second site for BlinkLab’s pivotal FDA 510(k) autism diagnostic trial. Pilot Phase Near Completion: BlinkLab’s 100-participant pilot study has been progressing towards completion, with results expected this quarter. Main Study Scaling: An additional 750–900…

  • Contains:
  • Biotechnology, Research Development
  • 08/07/2025
  • 06:00
Palin Communications

Taiwanese enterprises helping to make Australian health and wellbeing innovations a reality

Call continues for Australian submissions to “Go Healthy with Taiwan” 8 July 2025: The Taiwan Trade Centre in Sydney is continuing to encourage Australian…

  • Contains:
  • Biotechnology
  • 04/07/2025
  • 10:14
OncoSil Medical Limited (ASX:OSL)

OncoSil (ASX:OSL) Completion of Recruitment in PANCOSIL Study

Highlights: Patient recruitment for thePANCOSIL trial has now been successfully completed. This trial is an important part ofOncoSil Medical’s well-articulated clinical development strategy. The primary objective of thePANCOSIL trial is to assess a novel delivery method for the OncoSil™ device via a CT-guided percutaneous approach. OncoSil Medical expects preliminary data from the PANCOSIL study to be available in late 2025. Pancreatic cancer treatment device companyOncoSil Medical Limited (ASX:OSL) (“OncoSil” or “the Company”) is pleased to announce the successful completion of patient recruitment for the PANCOSIL Investigator Initiated Study. Achieving this milestone is yet another important step in the Company’s well-articulated…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.

Book a demo Explore our plans